Search PubMed⌕ Search

Biomedical subjects

L Potaux

Publications and source records attributed to L Potaux.

At least 91 records · Page 5Linked to original sources
PubMed1985

[Use of the receiver's own ureter, a remedial solution in lesions of the urinary tract, following renal transplantation].

An analysis of eleven cases in a series of 274 kidney transplantations between 1976 and 1984 suggests that pyeloureteral anastomosis with the recipient's own ureter only involves a simple operation, that the nephrectomy of the overlying kidney would not seem indispensable, that the existence of major infectious lesions is a contra-indication, and that seven of the eleven grafts were still functional with a followup of five months to seven years.

Adult↗
PubMed1984

[Surgical indications for primary vesico-ureteral reflux in adult candidates for renal transplantation].

Eight out of thirty five candidates for renal transplantation at the Bordeaux transplantation center, between 1975 and 1983, all presenting with primary vesico-ureteric reflux, underwent nephro-ureterectomy. The remaining twenty seven were not treated surgically. The authors consider that no operation is required when the ureter is narrow and uninfected, but that dilated refluant and infected ureters should be treated by nephro-ureterectomy, at least unilaterally. In that event, the operation is performed in two stages, with the second stage being performed at the same time as the transplantation.

Adult↗
PubMed1984

[Experimental magnesium ammonium phosphate lithiasis induced by Ureaplasma in the rat].

Struvite urinary stones are commonly associated with infections by urease possessing bacteria (Proteus). Ureaplasma urealyticum, a genital mycoplasma, is predominantly located in the human genito-urinary tract and produces urease. Its possible role in the formation of infection stones was studied in the rat model described by Friedlander and Braude. Struvite bladder stones were produced in 60% of Sprague-Dawley male rats after infection of ureaplasmas (serotype 1, 2, 3, 7) into the renal medulla. Mycoplasma hominis, another genital mycoplasma, produced bladder stones in only 10% of animals. A kinetic study showed that pure struvite stones appeared into the bladder 4 to 5 days after inoculation and that U. urealyticum did not usually remain viable more than 6 days. Acetohydroxamic acid and doxycycline prevented the formation of the stones.

Animals↗
PubMed1984

[Comparative bacteriological and chemical analysis of kidney calculi. Apropos of 135 cases].

The formation of some urinary tract stones (struvite stones) is known to be related to infection by urease-possessing microorganisms, such as Proteus sp. and some other bacteria. Ureaplasma urealyticum, a genital mycoplasma, contains also urease and is predominantly located in the urogenital tract. Its significance in the production of human urinary stones has not yet been elucidated. In this study, 135 human calculi obtained by surgery were analysed chemically and were cultured for the presence of conventional bacteria and U. urealyticum, 51 were ammonium magnesium phosphate stones and contained Proteus (27), E. coli (4), Staphylococcus epidermidis (3), Streptococcus D (2), Pseudomonas aeruginosa (1), Staphylococcus aureus (1), Corynebacterium (1), Candida albicans (1). U. urealyticum was isolated in one patient, from two different calculi (left and right) taken after an interval of fifteen days. Different bacteria were isolated from other calculi (oxalate, uric acid). This findings suggest that Ureaplasma urealyticum should be looked for in struvite calculi.

Bacteria↗
PubMed1983

Pharmacokinetics of tinoridine after oral administration to healthy subjects and patients with renal failure.

The pharmacokinetics of tinoridine was studied after oral administration (200, 400, and 800 mg in random order) to six healthy subjects and (200 mg) to patients with renal disease. Plasma concentrations of tinoridine were determined by GLC with electron-capture detection and urine concentrations by HPLC. The plasma half-life of tinoridine was about 8.2 h in healthy subjects and was not affected by renal failure. Total body clearance (Clc/F) was very high, but renal clearance was small, about 0.30 1.h-1. There was no correlation between dose (200 mg vs 400 or 800 mg) and Cmax or AUC, suggesting a first-pass effect. Renal failure did not affect pharmacokinetic parameters. However, there was a strong linear correlation between Cmax and age (r = 0.919) and AUC and age (r = 0.838). These results suggest an increase of bioavailability in the elderly.

Administration, Oral↗
PubMed1981

30 cases of second renal transplants.

30 second renal transplants from cadaver donors were performed. 93% of patients survived for 1 year and 89% for 2 years. 66% of grafts survived for 2 year and 57% for 2 years. Best results can be expected with patients less than 40 years old whose first transplant failed through chronic rejection, whether or not cytotoxic antibodies were present. The best histocompatibility in the HLA A and B system should be sought.

Adolescent↗
PubMed1980

Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

1 The pharmacokinetics of atenolol, after 200 mg orally, were studied in 18 patients with terminal renal insufficiency (creatinine clearance less than 5 ml/min), of whom twelve were being treated by chronic dialysis. 2 The peak plasma level, 1.59 +/- 0.43 mg/l, was reached in 4.7 +/- 2.1 h. 3 Without dialysis treatment, the apparent plasma half-life of atenolol was greatly increased (73.4 +/- 28.8 /). During dialysis, it dropped to 7.5 +/- 3.7 h but returned to 51.2 +/- 17.3 h after dialysis. The plasma atenolol plot was a rising slope for a few hours after the end of dialysis. 4 Renal clearance of atenolol was very low (4.6 +/- 1.5 ml/min). 5 Plasma clearance during dialysis was 42.6 +/- 21.3 ml/min for a mean blood flow-rate of 236 +/- 25 ml/min through a cuprophane membrane dialyser. 6 These results suggest that dosage should be modified for these patients.

Adult↗
PubMed1975

[Uricolytic therapy. Value of urate oxidase in the treatment of hyperuricemias].

In addition to uricosuric agents and purine synthesis inhibitors, Urate Oxydase may be used in the treatment of hyperuricaemia. This substance breaks down uric acid to allantoin which is soluble and easily excreted. Use of the medication in 14 cases of major gout with tophi and 9 cases of hyperuricaemia secondary to renal insufficiency showed the good tolerance of the substance and it's clinical and biological effectiveness.

Acute Kidney Injury↗